Michigan Archives

Sarcopenia in the Prostate Cancer Patient

Posted by Mark A. Moyad, MD, MPH | Apr 2020

Mark A. Moyad, MD, MPH, the Jenkins/Pokempner Director of Complementary/Alternative Medicine at the University of Michigan Medical Center in the Department of Urology, discusses the consequences of androgen-deprivation therapy-related skeletal muscle loss. He goes on to discuss the prevalence of sarcopenia in prostate cancer patients, the clinical studies demonstrating the efficacy of incorporating exercise for the prevention or mitigation of sarcopenia, as well as the benefits and limitations of diet and over the counter supplements for the prevention of sarcopenia.

State of the Art: Nutrition and Prostate Cancer

Posted by Mark A. Moyad, MD, MPH | Mar 2020

Mark A. Moyad MD, MPH, the Jenkins/Pokempner Director of Preventive/Complementary and Alternative Medicine (CAM) at the University of Michigan Medical Center in the Department of Urology, discusses how reducing caloric intake and improving heart health can help patients fight prostate cancer and reduce the odds of recurrent cancer. He also argues that experimenting with supplements along with cancer treatment can be disadvantageous and that over the counter drugs should only be taken with a certificate of analysis. Dr. Moyad further discusses how dietary changes for cancer patients will also improve their heart health, mental health, and quality of life.

Recent Clinical Radionuclide Therapy Advances in mCRPC

Posted by Ulka Vaishampayan, MD | Feb 2020

Ulka Vaishampayan, MD, Professor of Oncology at Wayne State University and Chief of Solid Tumor Oncology at the Karmanos Cancer Center, discusses the phase 3 randomized controlled trial of 177-Lutetium-PSMA radionuclide therapy. In this brief summary, Dr. Vaishampayan discusses the mechanism of action of this novel therapy, how to identify patients utilizing a PSMA-based PET scan, and the inclusion/exclusion criteria from the phase 3 randomized control trial of this targeted agent.

Prevalence of Criteria for Genetic Testing According to the National Comprehensive Cancer Network Guidelines in a Contemporary Cohort of Post-Prostatectomy Men with Intermediate and High-Risk Prostate Cancer: The Henry Ford Health System Experience

Posted by David Utz | Oct 2019

Zade Roumayah details the results of a study at the Henry Ford Health System examining the prevalence of National Comprehensive Cancer Network criteria for genetic testing in post-prostatectomy men who had intermediate- to high-grade prostate cancer. With around a 50% response rate, the team found that around 27% of men fit these criteria, in categories including family history of break & ovarian cancer, having two or more family members with a variety of cancer types, and personal cancer history.

Hormone Therapy in High Risk Prostate Cancer

Posted by Patrick W. McLaughlin, MD | Aug 2019

Patrick W. McLaughlin, MD, discusses balancing the therapeutic effects of androgen deprivation therapy (ADT) with the impact of quality of life (QOL). He examines the best timing and radiotherapy regimen combination to pair with ADT, as well as properly assessing individual patients’ risk factors and disease severity when choosing treatment options.